Lupin's Q1 FY 2026-27 Quarterly Results

Result Summary

• Lupin Ltd reported a 10.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 32.5%.
• Its expenses for the quarter were up by 15.0% QoQ and 29.6% YoY.
• The net profit decreased 3.5% QoQ and increased 16.0% YoY.
• The earnings per share (EPS) of Lupin Ltd stood at 30.89 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lupin Ltd is a pharmaceutical company engaged in the development and production of a wide range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. The company operates primarily within the healthcare and pharmaceutical industry. Lupin Ltd's diversified portfolio includes therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives, and non-steroidal anti-inflammatory drugs (NSAIDs). As of the latest available data, there are no specific recent major developments or acquisitions noted for Lupin Ltd.

Revenue

In Q1FY27, Lupin Ltd reported a total income of ₹8407.21 crores, reflecting a robust growth of 10.4% compared to the previous quarter (Q4FY26) and a significant year-over-year increase of 32.5% compared to Q1FY26. This positive trend in revenue indicates a consistent upward trajectory in the company's income generation over the past year, demonstrating its capacity to enhance its market presence and sales volume in the competitive pharmaceutical sector.

Profitability

For the quarter ended Q1FY27, Lupin Ltd achieved a profit before tax of ₹2017.38 crores, marking a quarter-over-quarter increase of 4.6% and a year-over-year growth of 42.5%. The company's profit after tax for the same period was ₹1416.98 crores, which decreased by 3.5% from the previous quarter but increased by 16.0% on a year-over-year basis. Earnings per share for Q1FY27 were ₹30.89, showing a reduction of 3.1% from Q4FY26, yet a 16.0% rise from Q1FY26. The tax expense for this quarter was ₹600.38 crores, which increased by 30.7% quarter-over-quarter and surged by 209.3% year-over-year, reflecting changes in the company's tax liabilities.

Operating Metrics

Lupin Ltd's total expenses for Q1FY27 were ₹6389.83 crores, witnessing a 15.0% increase compared to Q4FY26 and a 29.6% rise compared to Q1FY26. This increase in expenses corresponds with the overall growth in revenue, indicating an expansion in operational activities. The company's ability to manage its cost base relative to revenue growth is crucial for sustaining profitability levels. The observed trends in the financial metrics offer a view into the company's operational efficiency and its strategic emphasis on scaling up its business activities within the pharmaceutical industry.